Taika Capital LP Makes New $1.79 Million Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Taika Capital LP purchased a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 36,775 shares of the company's stock, valued at approximately $1,785,000. Amphastar Pharmaceuticals comprises about 1.3% of Taika Capital LP's holdings, making the stock its 25th largest holding. Taika Capital LP owned approximately 0.08% of Amphastar Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Victory Capital Management Inc. lifted its position in shares of Amphastar Pharmaceuticals by 10.9% during the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company's stock worth $10,605,000 after purchasing an additional 21,530 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $11,070,000. Intech Investment Management LLC acquired a new position in Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $426,000. Los Angeles Capital Management LLC acquired a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $785,000. Finally, Glenmede Trust Co. NA raised its holdings in Amphastar Pharmaceuticals by 145.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 37,884 shares of the company's stock valued at $1,839,000 after acquiring an additional 22,439 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, EVP Yakob Liawatidewi sold 5,214 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the sale, the executive vice president now directly owns 74,938 shares of the company's stock, valued at approximately $3,900,522.90. The trade was a 6.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 7,426 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at approximately $4,898,061.15. This trade represents a 7.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,533 shares of company stock worth $1,238,842. Insiders own 27.10% of the company's stock.

Amphastar Pharmaceuticals Trading Up 0.5 %

AMPH traded up $0.23 during mid-day trading on Friday, reaching $43.83. The stock had a trading volume of 133,794 shares, compared to its average volume of 398,583. The stock has a market capitalization of $2.11 billion, a P/E ratio of 14.53, a P/E/G ratio of 0.89 and a beta of 0.78. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm's fifty day simple moving average is $47.59 and its two-hundred day simple moving average is $44.59. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Finally, Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.